2017 No. 1114

Dangerous Drugs

The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2017

Made

Coming into force

At the Court at Buckingham Palace, the 15th day of November 2017

Present,

The Queen’s Most Excellent Majesty in Council

In accordance with section 2(5) of the Misuse of Drugs Act 19711 a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.

Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:

Citation and commencement1

This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2017 and comes into force on the 27th November 2017.

Amendment to the Misuse of Drugs Act 1971

2

The following amendment is made to Schedule 2 to the Misuse of Drugs Act 1971.

3

In paragraph 1(a) of Part 2 (which specifies the drugs which are subject to control under that Act as Class B drugs) after “Methylphenobarbitone” insert—

N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA).

Ceri KingDeputy Clerk of the Privy Council
EXPLANATORY NOTE

(This note is not part of the Order)

This Order brings certain drugs under the control of the Misuse of Drugs Act 1971 (‘the Act’). Article 3 of this Order brings methiopropamine or MPA related materials under permanent control as Class B drugs under the Act. These methiopropamine or MPA related materials were specified under section 2A of the Act as drugs subject to temporary control by virtue of the Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2016 (S.I. 2016/1126) and cease to be subject to such temporary control on the coming into force of this Order in accordance with section 2A(6)(b) of the Act.